Streetbeat News

Regulatory

ME

23andMe has regained compliance with Nasdaq's minimum closing bid price requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 9:11 pm

NJR

New Jersey Natural Gas has received approval from the New Jersey Board of Public Utilities for the next generation of its SAVEGREEN program, which focuses on energy-efficiency solutions and emissions reduction for residential and commercial customers.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:57 pm

AZTA

Azenta, Inc. (NASDAQ:AZTA) has launched a long-read Whole Genome Sequencing test for clinical applications, becoming the first commercial provider to obtain regulatory approval for this test in the US. This test, using PacBio's Revio sequencer, offers more accurate detection of genetic variants in complex genomic regions, aiding in the diagnosis and treatment of rare diseases.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:48 pm

QQQ

SPY

The Federal Reserve's preferred inflation measure, the PCE price index, is expected to show a decline in September, reinforcing the disinflationary trend. This could support expectations for continued Fed rate cuts in 2024 and 2025. Market reactions will depend on whether the data meets expectations, with potential positive impacts on stocks and declining bond yields if inflation is controlled.

Portfolio Pulse from Piero Cingari

October 30, 2024 | 8:37 pm

ALTR

Trading for ALTR was halted at 4:27:00 p.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:27 pm

HIMS

NVO

Hims & Hers Health Inc. (NYSE:HIMS) shares fell after the FDA announced the availability of Novo Nordisk's (NYSE:NVO) drugs Ozempic and Wegovy, which may end the demand for compounded versions that Hims & Hers benefited from.

Portfolio Pulse from Vaishali Prayag

October 30, 2024 | 8:20 pm

HOOD

Robinhood has announced its expected GAAP total operating expenses for fiscal year 2024 to be between $1.86 billion and $1.96 billion. This includes a $10 million regulatory accrual in the third quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:13 pm

IVA

Inventiva announced that the Data Monitoring Committee has recommended the continuation of their clinical trial without any modifications to the current protocol, following a pre-planned review of safety data.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:05 pm

IVA

Inventiva's NATiV3 Phase 3 clinical trial for lanifibranor in MASH patients continues as planned, following a positive safety review by the Data Monitoring Committee.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:01 pm

MCD

SPY

The CDC reports an E. Coli O157:H7 outbreak affecting 90 people across 13 U.S. states as of October 30. This could impact companies in the food industry, such as McDonald's, and broader market indices like SPY.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 7:45 pm